MA32003B1 - Vaccin - Google Patents

Vaccin

Info

Publication number
MA32003B1
MA32003B1 MA32991A MA32991A MA32003B1 MA 32003 B1 MA32003 B1 MA 32003B1 MA 32991 A MA32991 A MA 32991A MA 32991 A MA32991 A MA 32991A MA 32003 B1 MA32003 B1 MA 32003B1
Authority
MA
Morocco
Prior art keywords
viral vector
seq
relates
protein
malaria
Prior art date
Application number
MA32991A
Other languages
Arabic (ar)
English (en)
Inventor
Joseph D Cohen
Martine Marchand
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32003(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA32003B1 publication Critical patent/MA32003B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention porte sur un vecteur adénoviral simien c7 défectif pour la réplication, encodant une protéine incluant une protéine cs de p. Falciparum ou un fragment de celle-ci, ainsi qu'illustré, par exemple, dans la seq id : 1 ou la seq id : 3. L'invention porte également sur des procédés de préparation dudit vecteur viral et sur l'utilisation de celui-ci dans le traitement / la prévention des infections du type paludisme. L'invention concerne également des compositions, des vaccins et des kits contenant ledit vecteur viral. Dans un aspect, l'invention recourt à un vecteur viral c7 de synthèse. Le vecteur viral c7 selon l'invention peut être administré conjointement ou formulé conjointement à un antigène du paludisme tel que rtss, éventuellement en présence d'un adjuvant incluant par exemple un 3d-mpl et/ou une saponine qs-21.
MA32991A 2007-12-06 2010-07-05 Vaccin MA32003B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99280207P 2007-12-06 2007-12-06
PCT/EP2008/066762 WO2009071613A2 (fr) 2007-12-06 2008-12-04 Vaccin

Publications (1)

Publication Number Publication Date
MA32003B1 true MA32003B1 (fr) 2011-01-03

Family

ID=40591828

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32991A MA32003B1 (fr) 2007-12-06 2010-07-05 Vaccin

Country Status (20)

Country Link
EP (1) EP2227550A2 (fr)
JP (1) JP2011505796A (fr)
KR (1) KR20100108544A (fr)
CN (1) CN101939438A (fr)
AR (1) AR069568A1 (fr)
AU (1) AU2008333208A1 (fr)
BR (1) BRPI0819889A2 (fr)
CA (1) CA2707245A1 (fr)
CL (1) CL2008003614A1 (fr)
CO (1) CO6300795A2 (fr)
CR (1) CR11537A (fr)
DO (1) DOP2010000164A (fr)
IL (1) IL205953A0 (fr)
MA (1) MA32003B1 (fr)
MX (1) MX2010006207A (fr)
PE (1) PE20091106A1 (fr)
TW (1) TW200938633A (fr)
UY (1) UY31510A1 (fr)
WO (1) WO2009071613A2 (fr)
ZA (1) ZA201003851B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0815872D0 (en) * 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB201016471D0 (en) * 2010-09-30 2010-11-17 Isis Innovation Viral vector immunogenic compositions
CA2832307A1 (fr) 2011-04-08 2012-10-18 Immune Design Corp. Compositions immunogenes et leurs procedes d'utilisation pour induire des reponses immunitaires humorales et cellulaires
CN110687289B (zh) * 2019-10-17 2023-04-18 中国人民解放军陆军军医大学 Fgl2蛋白作为疟疾感染标志物的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
AU2003285932A1 (en) * 2002-10-23 2004-05-13 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
NZ539813A (en) * 2002-12-17 2008-04-30 Crucell Holland Bv A replication defective recombinant adenovirus comprising a antigenic determinant of Plasmodium falciparum wherein the antigenic determinant is SEQ ID 6
WO2005063805A1 (fr) * 2003-12-23 2005-07-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps dirige contre la zone de terminus amino de la proteine circumsporozoite, pour prevenir l'apparition d'infections paludeennes
EP1711518B1 (fr) * 2004-01-23 2009-11-18 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Porteurs de vaccin adenoviral de chimpanze
RS52187B (sr) * 2004-10-14 2012-10-31 Crucell Holland B.V. Vakcine za indukciju i stimulaciju imunskog odgovora za malariju
GB0513421D0 (en) * 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
US20090110695A1 (en) * 2006-03-27 2009-04-30 Menzo Jans Emko Havenga Compositions Comprising a Recombinant Adenovirus and an Adjuvant
WO2008009652A2 (fr) * 2006-07-18 2008-01-24 Glaxosmithkline Biologicals S.A. Vaccins contre le paludisme
EP2998316B1 (fr) * 2007-03-02 2019-06-12 GlaxoSmithKline Biologicals S.A. Nouveau procédé et nouvelles compositions
GB0706914D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors

Also Published As

Publication number Publication date
AR069568A1 (es) 2010-02-03
JP2011505796A (ja) 2011-03-03
WO2009071613A2 (fr) 2009-06-11
CR11537A (es) 2010-08-18
BRPI0819889A2 (pt) 2015-06-16
MX2010006207A (es) 2010-10-04
CA2707245A1 (fr) 2009-06-11
DOP2010000164A (es) 2010-07-31
IL205953A0 (en) 2010-11-30
AU2008333208A1 (en) 2009-06-11
PE20091106A1 (es) 2009-08-24
UY31510A1 (es) 2009-08-03
CL2008003614A1 (es) 2010-01-15
ZA201003851B (en) 2012-11-28
TW200938633A (en) 2009-09-16
CO6300795A2 (es) 2011-07-21
KR20100108544A (ko) 2010-10-07
WO2009071613A3 (fr) 2009-08-13
EP2227550A2 (fr) 2010-09-15
CN101939438A (zh) 2011-01-05

Similar Documents

Publication Publication Date Title
MA33449B1 (fr) Antigènes recombinants du vrs
MA29406B1 (fr) Vaccin toxoide alpha de c. perfringens
WO2009072767A3 (fr) Composition puissante d'un vaccin comprenant un lipopeptide et poly i:c comme adjuvant
NO20074392L (no) Vaksine
MA30670B1 (fr) Vaccins contre le paludisme
NO20082472L (no) Vaksinesammensetninger omfattende en saponin adjuvant
NZ612315A (en) Compositions for immunising against staphylococcus aureus
Coppola et al. Synthetic long peptide derived from Mycobacterium tuberculosis latency antigen Rv1733c protects against tuberculosis
MX2010001054A (es) Composiciones adyuvantes antigenicas y metodos.
CL2008003197A1 (es) Anticuerpo que se une especificamente a la region n-terminal del peptido alfa-beta8-x; hibridoma y proceso de preparacion del anticuerpo; metodo para detectar la carga amiloide in vitro en un mamifero; kit, composicion terapeutica y de vacuna que comprenden al anticuerpo; uso del anticuerpo para tratar la enfermedad de alzheimer.
EE200200507A (et) Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine
MA31093B1 (fr) Vaccin
NO20076239L (no) Peptidkonjugatpreparater og fremgangsmater for forebygging og behandling av Alzheimers sykdom
BRPI0619357A8 (pt) Anticorpos monoclonais, composição farmacêutica, vacina, uso dos mesmos para tratamento ou prevenção de doença de alzheimer, métodos in vitro para diagnosticar e para identificar compostos apropriados para imunização de doença de alzheimer e kits
MA29601B1 (fr) Vaccin antipaludeen
AR093712A1 (es) Composicion inmunogena, vacuna, uso y procedimiento de prevencion o tratamiento
MA32003B1 (fr) Vaccin
MA40769A (fr) Indoles mono ou di-substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
AU2020256283A8 (en) Porcine circovirus type 3 (PCV3) vaccines, and production and uses thereof
JP2017508006A5 (fr)
DOP2010000189A (es) Vacunas contra la malaria
KR20150032266A (ko) Ｃｒｍ１９７ 담체 단백질에 커플링된 ｈｉｖ ｇｐ４１ 펩티드를 포함하는 면역원성 화합물
AU2002310474A1 (en) Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same
TNSN08184A1 (en) Chimeric antigens and vaccines
MA32029B1 (fr) Vaccins contre la malaria